Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. Summary
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
0.89(c) 0.891(c) 0.9038(c) 0.9271(c) 0.8844 Last
205 597 160 613 294 870 155 609 90 280 Volume
-3.20% +0.11% +1.44% +2.58% -4.61% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2,21 M - -
Net income 2022 -12,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,47x
Yield 2022 -
Sales 2023 7,49 M - -
Net income 2023 -8,15 M - -
Net Debt 2023 - - -
P/E ratio 2023 -10,7x
Yield 2023 -
Capitalization 82,0 M 82,0 M -
Capi. / Sales 2022 37,2x
Capi. / Sales 2023 11,0x
Nbr of Employees 13
Free-Float 97,5%
More Financials
Company
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. It has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/08 | 12:00pmShareholder meeting
More about the company
Ratings of Lipocine Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about LIPOCINE INC.
05/12Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Exten..
MT
05/12LIPOCINE INC. : Financial Statements and Exhibits (form 8-K)
AQ
05/12LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/12Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
PR
05/12Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results
CI
05/09LIPOCINE : Q1 Earnings Snapshot
AQ
05/09LIPOCINE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/09LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/09Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
PR
05/09Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/25Lipocine Inc. Grants Antares Pharma an Exclusive License to Commercialize TLANDO in the..
CI
04/11LIPOCINE : ANNOUNCES BOARD of DIRECTOR APPOINTMENTS - Form 8-K
PU
04/11LIPOCINE INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
AQ
04/11LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
PR
04/11Lipocine Inc. Announces Board Appointments
CI
More news
News in other languages on LIPOCINE INC.
05/12Lipocine dit que le traitement de la stéatohépatite non alcoolique est bien toléré dans..
05/12Lipocine Inc. Annonce des résultats positifs de l'étude de prolongation ouverte LPCN 11..
05/09Lipocine Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/25Lipocine Inc. accorde à Antares Pharma une licence exclusive pour la commercialisation ..
04/11Lipocine Inc. annonce des nominations au conseil d'administration
More news
Analyst Recommendations on LIPOCINE INC.
More recommendations
Chart LIPOCINE INC.
Duration : Period :
Lipocine Inc. Technical Analysis Chart | LPCN | US53630X1046 | MarketScreener
Technical analysis trends LIPOCINE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,93 $
Average target price 3,67 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Mahesh V. Patel Chairman, President, Chief Executive Officer & CFO
Anthony DelConte Chief Medical Director
Richard Dana Ono Independent Director
Jeffrey Arvin Fink Independent Director
Jill M. Jene Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIPOCINE INC.-6.46%82
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666